Executive summary
U.S. Patent 9,284,371 claims a process for producing adalimumab in large-scale mammalian cell culture (typically CHO) using stepwise or ramped pH reduction and fed supplementation (without removing the medium), combined with Protein A affinity purification. The dependent claims narrow to glucose feed control (trigger <2 g/L; target 2 to 7 g/L), temperature shift (35 to 38°C down to 32 to 33°C), specific hydrolysate mixes (soy and yeast hydrolysates), and process operating windows (osmolarity ≤440 mOsm; ~30% dissolved oxygen).
From an enforcement and freedom-to-operate (FTO) perspective, the claim set is structured as (i) a broad “fed-batch style” framework with pH shift + nutrient supplement + Protein A, then (ii) multiple additional levers that can be used for both attack (non-infringement by omission or different setpoints) and validity pressure (obviousness combinations of known upstream feeds, pH shifts, and downstream Protein A). The key practical question in infringement is whether a defendant’s process includes the specific combinations and operational ceilings/thresholds (pH 8 or less down to 6.5–7; glucose control <2 g/L trigger and 2–7 g/L window; temperature 35–38 to 32–33; osmolarity ≤440; DO ~30%), not merely whether it uses a CHO fed-batch and Protein A.
U.S. Patent 9,284,371 landscape: what claims protect for adalimumab manufacturing using pH shift, fed supplementation, and Protein A
Bottom line on claim coverage
- Core claim concept (claim 1): adalimumab production in large-scale mammalian cells where pH is lowered during culture, medium is not removed but supplemented with glucose or other nutrients at least once, and product is purified using Protein A affinity.
- Main commercially meaningful narrowing features (claims 3–4, 5, 8, 10, 9, 6–7):
- Glucose monitoring and feeding: add if <2 g/L, then aim 2 to 7 g/L.
- Temperature shift: initial 35–38°C, then 32 or 33°C.
- Medium composition/quality windows: osmolarity ≤440 mOsm, DO ~30%.
- pH window: first pH ≤8, then second pH 6.5–7, with possible pH ramp.
- Defined hydrolysates and supplements (soy + yeast hydrolysates; PFCHO; “yeastolate” solution types).
- Yield guardrails: ≥2 g/L (and in some dependents ≥1.5 g/L).
Claim anatomy that matters for infringement
U.S. method claims require all stated process steps/conditions. For defendants, non-infringement routes are typically to:
- Run a different pH trajectory (e.g., do not reach 6.5–7, or start above 8),
- Avoid a glucose trigger tied to <2 g/L, or do not hold 2–7 g/L,
- Use a temperature schedule outside 32–33°C shift,
- Operate at osmolarity >440 mOsm or different DO control,
- Use alternative downstream capture (or not “including Protein A affinity purification” as required by the claim language),
- Replace soy/yeast hydrolysate mix with different defined supplements (where dependents are asserted).
What are the independent and dependent claims in U.S. Patent 9,284,371 and how do they map to real adalimumab CDMO unit ops?
Claim 1 (key independent claim) protected process pattern
- Upstream
- Large-scale mammalian cell culture expressing adalimumab
- pH adjusted from first pH to second pH during culturing, with second pH lower
- Medium not removed but supplemented with glucose or other nutrients at least once
- Downstream
- Purify adalimumab from the cell culture medium using a process including Protein A affinity purification
Claim 2 (supplementation timing breadth)
- Medium supplemented more than once
- Optional schedules: continuous, daily, every other day, every two days, combinations
Claim 3–4 (glucose monitoring and setpoint window)
- Feed glucose when glucose <2 g/L
- Set glucose ≥2 g/L and ≤7 g/L
Claim 5 (temperature shift pair)
- Initial temperature 35, 37, or 38°C
- Reduced temperature 32 or 33°C
Claim 6–7 (hydrolysate and supplement specificity)
- Medium comprises soy-based hydrolysate + yeast-based hydrolysate
- Example adds: 25x PFCHO solution and 33x “yeastolate” combination (as stated)
Claim 8 (operating window specificity for cell physiology)
- Osmolarity ≤440 mOsm
- ~30% dissolved oxygen
- CHO cells
Claim 9 (yield)
- adalimumab yield in the cell culture production medium ≥2 g/L
Claim 10–11 (pH windows and ramp)
- First pH ≤8
- Second pH 6.5 to 7
- If glucose falls below 2 g/L, add glucose to bring it back into 2–7 g/L
Claims 12–14 (yield, osmolarity/DO) further narrow
- Yields: ≥1.5 g/L or ≥2 g/L
- plus CHO + osmolarity/DO where stated
Claims 17–19 (composition variants)
- non-animal-based hydrolysate (dependent)
- soy + yeast hydrolysate variant
- CHO + defined supplement inputs
Claim 20 (pH ramp)
- first pH adjusted to reduced pH via pH ramp
Claim 21–30 (alternative claim framing to combine upstream levers in a single dependent set)
- Claim 21: temperature shift + fed supplementation (nutrient at least once) + Protein A
- Claim 23: pH initial to reduced via ramp with pH windows
- Claim 29 (broadest among the re-framed dependent set): combines multiple elements in one method:
- pH windows (≤8 to 6.5–7),
- temperature shift,
- medium not removed but supplemented with glucose,
- medium also supplemented with nutrient other than glucose at least once,
- Protein A purification
- Claim 30: CHO + soy/yeast hydrolysates
Enforcement implication
Because multiple dependents introduce tight operational windows, the strongest infringement cases typically occur where a defendant’s process is close to the described operating envelope, including both pH and feed control.
How strong is the patent estate for adalimumab fed-batch pH shift and glucose feeding (Protein A purification) against generic and biosimilar process challenges?
What “strength” means here
- For manufacturing process patents, strength depends less on novelty of Protein A and more on whether the specific process parameters and feeding logic are non-obvious relative to prior art combinations, and whether infringement can be proven step-by-step.
Likely obviousness fault lines
Even without evaluating file history, the claim set concentrates multiple features that are individually common in biologics manufacturing:
- pH setpoint control and downshift during culture
- fed-batch style nutrient additions without full medium removal
- glucose feeding based on monitoring
- temperature shifts to enhance productivity (common in CHO processes)
- Protein A downstream capture (standard in monoclonal antibody purification)
A validity attack typically argues that a skilled person would combine known upstream controls:
- To reduce acidification or modulate metabolism via pH shift
- To manage carbon source and avoid starvation by feeding glucose within a target window
- To shift temperature late in culture to improve productivity/quality
- While still using Protein A capture
The dependent claims with hard numeric windows (pH 6.5–7; glucose 2–7 g/L; osmolarity ≤440 mOsm; DO ~30%; temperature to 32–33°C) reduce prior-art overlap if those exact windows were not taught, but they also become more vulnerable if prior art broadly teaches similar ranges and it would be routine to optimize.
Practical enforceability constraints
To win on a process claim, plaintiffs generally need:
- discovery and documentation showing how the cells were run (feeds, timing, monitoring-trigger logic, pH ramp implementation)
- linkage that the defendant’s downstream purification “includes Protein A affinity purification” as claimed
Process patents face discovery-heavy litigation, and the party asserting often targets those steps.
Net effect
The claims appear most defensible where the prior art lacks a clear teaching of the combination of:
- pH lowered to 6.5–7 with first pH ≤8 (and pH ramp option),
- medium not removed but supplemented at least once (fed-batch character),
- glucose added when below <2 g/L and held 2–7 g/L,
- plus temperature shift to 32–33°C,
- under CHO-specific osmolarity and DO windows.
When does U.S. Patent 9,284,371 expire and what exclusivity does it affect for adalimumab?
Not computable from the provided data
The expiration date depends on:
- filing date, priority date, and patent term adjustments (PTA) and any terminal disclaimers, none of which are provided in the prompt.
No complete or accurate exclusivity timeline can be produced from the information supplied.
What patents protect adalimumab manufacturing methods like Protein A purification plus pH/glucose/temperature setpoints?
Key issue
U.S. Patent 9,284,371 claims a specific manufacturing method, not the antibody itself. In the adalimumab ecosystem, related patent families commonly include:
- cell culture process controls (pH, feeds, temperature, oxygen, osmolarity)
- medium formulations (hydrolysates, supplements)
- platform purification steps (Protein A capture; polishing steps)
- analytics and quality control release criteria
- formulation/USP drug product patents (not claimed here)
Given the provided claim text, 9,284,371’s most directly protected elements are:
- pH shift from ≤8 to 6.5–7 (or general “first pH to lower second pH” in claim 1)
- fed supplementation logic without removing medium
- glucose monitoring-trigger and target window
- temperature reduction to 32–33°C
- CHO + soy/yeast hydrolysate combinations
- operating window for osmolarity and DO
- Protein A affinity purification inclusion
Enforcement focus
This kind of patent is typically asserted against other manufacturers’ process development decisions and scale-up batches where parameter settings match the claim.
How do you assess claim infringement for U.S. Patent 9,284,371: what elements must be present in the accused adalimumab process?
Claim 1 infringement checklist (must satisfy all)
- Large-scale mammalian cells expressing adalimumab
- pH adjusted from first pH to a lower second pH during culturing
- Cell culture medium not removed but supplemented with glucose or other nutrients at least once
- Purify adalimumab from the medium using a process including Protein A affinity purification
Dependent claim traps (typical design-around levers)
- Glucose feed logic: avoid the <2 g/L trigger and/or the 2–7 g/L target
- Temperature: avoid the 32–33°C reduction after 35–38°C initial temperature
- pH windows: keep second pH outside 6.5–7 or first pH above 8
- Osmolarity and DO: run outside ≤440 mOsm or not at ~30% DO (as claimed)
- Hydrolysates: avoid the specified soy/yeast hydrolysate combination and/or named supplement solutions where dependents are asserted
- Multi-nutrient feeding: if asserting claim 29, avoid feeding a nutrient other than glucose at least once
Process proof requirement
Because the claim is conditional on measured process parameters (glucose levels, osmolarity, DO, pH ramp), plaintiffs typically need:
- batch records or run logs
- media formulation and feed schedules
- instrument calibration records
- purification process descriptions showing Protein A affinity steps
What generic or biosimilar entry risks exist for adalimumab tied to this manufacturing-method patent?
Risk mechanism
This patent targets the manufacturing process, not the drug product formulation or labeling. For biosimilars, the risk is:
- higher if the biosimilar manufacturer’s process is similar to the claimed upstream control strategy
- amplified if the biosimilar applicant must document comparability that reveals the process parameters, or if discovery in litigation reveals batch specifics
Risk reduction paths
Typical risk reduction is to redesign:
- pH trajectory and ramp implementation
- feed triggers and target glucose windows
- temperature shift timing and magnitude
- oxygen and osmolarity setpoints
- hydrolysate blends and nutrient supplementation plan
- and potentially purification steps (though many still use Protein A in some form)
Net effect
The core claim 1 is broader than most dependents, so design-arounds must address multiple levers at once, not only a single parameter.
How does U.S. Patent 9,284,371 compare with typical monoclonal antibody process patents (fed-batch pH, nutrient feed, and Protein A capture)?
Comparative structure
Most mAb process patents fall into:
- media formulation and feeding strategies
- cell culture control (pH, temperature, oxygen)
- downstream purification
U.S. Patent 9,284,371’s distinguishing aspect is the combination of:
- pH downshift into a defined window (in dependents)
- glucose monitoring and maintaining a defined range
- explicit temperature reduction to 32–33°C
- and CHO-relevant medium and operating windows
- all paired with Protein A purification inclusion
Implication for litigation
Defendants can often accept that fed-batch with Protein A is standard, but they must contest whether the accused process matches the narrow parameter windows (especially where dependents are asserted).
What jurisdictions and claim scope matter for U.S. Patent 9,284,371?
Provided data limitation
The prompt provides only the U.S. patent and claim text. No foreign family details, continuation status, or other jurisdictional filings are provided.
No complete multi-jurisdiction analysis can be produced from the information supplied.
What adalimumab manufacturing features are likely required by the claim set (pH ramp, glucose threshold, temperature shift, soy/yeast hydrolysates, CHO, osmolarity, DO) and how do they affect process scale-up?
Upstream control features (high-level mechanics)
- pH shift during culture changes CO2 balance, acid metabolism outcomes, and proteostasis
- glucose feeding to a 2–7 g/L window is typically used to manage energy supply and limit byproduct accumulation
- temperature downshift to 32–33°C often improves folding/quality attributes and reduces protease activity later in run cycles
- osmolarity and DO affect growth rate and metabolic state; tightly controlled windows suggest a reproducible productivity/quality target
- hydrolysate blends can provide peptides/amino acids and complex nutrients, often needed to sustain productivity in a chemically defined or hybrid medium
Downstream link (Protein A)
Protein A capture is the major affinity step for IgG Fc-containing monoclonal antibodies and is commonly used across adalimumab-like manufacturing lines. In this claim set it is required as an “including” step, which in practice means an accused process that omits Protein A affinity capture is less likely to infringe claim 1.
Key takeaways
- U.S. Patent 9,284,371 protects a manufacturing method for adalimumab defined by pH reduction, fed supplementation without medium removal, and Protein A affinity purification, with dependents tightening into specific operational windows.
- The strongest infringement leverage typically comes from processes that match (i) pH ≤8 down to 6.5–7 (with ramp option), (ii) glucose feeding when <2 g/L to hold 2–7 g/L, (iii) temperature downshift to 32–33°C, and (iv) CHO conditions including osmolarity ≤440 mOsm and ~30% DO.
- Common mAb manufacturing steps like Protein A capture, fed-batch nutrient additions, and pH/temperature control are not enough on their own to establish infringement; accused processes must map to the specific claimed combinations and numeric ranges, at least where those dependents are asserted.
- The claim architecture supports both design-around (shift one or more numeric windows and feed logic) and assertion focused on detailed batch documentation.
FAQs
1) Does claim 1 require glucose specifically, or is “glucose or one or more other nutrients” enough?
Claim 1 requires supplementation with glucose or one or more other nutrients at least once; glucose is not strictly mandatory if other nutrients are supplemented.
2) If a process adjusts pH but does not use Protein A, is it outside U.S. Patent 9,284,371?
Yes, because claim 1 requires purification “using a process including Protein A affinity purification.” Omitting Protein A affinity capture is a direct non-infringement path for claim 1.
3) For dependent claim 3 and 4, what is the critical glucose parameter?
The critical elements are the monitoring trigger (glucose determined after monitoring is below 2 g/L) and the target window (at least 2 g/L but ≤7 g/L).
4) Do the temperature limitations apply only in claim 5 and related dependents, or are they part of claim 1?
They are not part of claim 1. Claim 5 introduces the specific temperature schedule (35/37/38°C reduced to 32 or 33°C), and related dependents incorporate it.
5) Is osmolarity control part of the independent claim?
No. Osmolarity and DO are in claim 8 (and incorporated in related claim sets), not in claim 1.
References (APA)
No external sources were cited because the prompt provided only the claim text and did not include patent bibliographic details (publication number, filing/priority dates, prosecution history, or related family documents) needed for factual citations.
